Flexion's raring to launch its knee injection Zilretta, and it's floating a $100 million-plus stock offering to make that happen.

A physician survey suggests new drugs to treat tardive dyskinesia—Neurocrine’s Ingrezza, in particular—may capture sales that beat current expectations.

Goodbye to Belsomra's furry-word mascots. Now, instead of a "sleep" cat and "wake" dog, Merck has debuted a new empathy-oriented TV…

Sanofi's new diabetes and CV chief says new meds need to offer clear advantages to make it in today's tough environment.

Roche took a step toward beefing up Perjeta sales Friday with priority review for a Herceptin combo. But can the pairing really win over doctors?

Which biotech company does Vertex admire? Hint: It’s one some analysts think the CF drugmaker should bought a long time ago.

With its latest FDA nod, Bristol-Myers Squibb’s Opdivo won the right to take on Bayer's Stivaga in liver cancer.

Steve Miller, CMO of Express Scripts, is not mincing words in his assessment of Kymriah, Novartis' $475,000 CAR-T treatment for leukemia.